表紙
市場調査レポート

オクトレオチドの中国市場の分析

Investigation Report on China Octreotide Market, 2010-2019

発行 China Research and Intelligence 商品コード 332767
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
オクトレオチドの中国市場の分析 Investigation Report on China Octreotide Market, 2010-2019
出版日: 2015年06月11日 ページ情報: 英文 30 Pages
概要

オクトレオチドは、中国ではNovartisにより2004年より上市されました。現在では多数の国内系メーカーによりジェネリック医薬品が製造・販売されています。オクトレオチドは様々な疾患の治療に使えることから、需要が急激に増加しており、2005年には1億人民元だった市場規模は、それ以降は15.8%もの年平均成長率 (CAGR) で成長し、2014年には4億6600万人民元にまで拡大しました。今後もこの傾向が続くものと思われます。

当レポートでは、中国におけるオクトレオチドの市場について分析し、全体的な市場規模の動向(過去5年間分)や国内価格の動向、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査・推計しております。

第1章 オクトレオチドの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国のオクトレオチド市場の概況

  • 中国国内でのオクトレオチド特許の出願・認証状況
  • 主要メーカー
  • 市場規模

第3章 オクトレオチドの販売状況の分析 (過去5年間分)

  • 販売額
    • 全体的な販売額
    • 地域別の販売額
  • 販売量
    • 全体的な販売量
    • 地域別の販売量

第4章 中国のオクトレオチド市場:主要メーカーの市場シェアの分析 (過去5年間分)

  • 市場シェア (販売額ベース)
  • 市場シェア (販売量ベース)

第5章 中国のオクトレオチド市場:剤形別の分析 (過去5年間分)

  • 剤形別の市場シェア (販売額ベース)
  • 剤形別の市場シェア (販売量ベース)

第6章 オクトレオチドの病院向け基準価格

  • Sandoz GmbH (AT) (商標名:Sandostatin LAR)
  • Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd
  • Wellso Pharmaceutical Co., Ltd
  • Peking Sunho Pharmaceutical Co., Ltd
  • Sinopharm A-THINK Pharmaceutical Co., Ltd
  • GeneScience Pharmaceuticals Co., Ltd
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd
  • Novartis AG (Sweden) (商標名:Sandostatin LAR)

第7章 中国国内のオクトレオチド主要メーカー

  • Novartis AG (Switzerland)
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd
  • Sinopharm A-THINK Pharmaceutical Co., Ltd
  • Peking Sunho Pharmaceutical Co., Ltd
  • Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd

第8章 中国のオクトレオチド市場の将来展望 (今後5年間分)

  • 市場規模の予測
  • 競争環境の見通し

図表一覧

目次
Product Code: 1506211

Octreotide, an octapeptide that mimics natural somatostatin, has been widely used in clinic for the treatment of upper gastrointestinal variceal hemorrhage and stomach ulcer bleeding, acute pancreatitis, endocrine tumors.

First approved to be sold in 1996, octreotide was developed by Novartis AG under the trade name of Sandostatin. The approved indications at that time were acromegaly, diarrhea and pancreatic cancer. Due to its sure efficacy and various indications, octreotide has become one of the most highly stressed biosimilar compounds. Octreotide has remained a steady growth ever since its listing and its sales value surpassed USD 1000 million in 2007. Sandostatin's US patent expired in Jun. 2014. Although the generic drug of octreotide made by Sun Pharmaceutical Industries Ltd got FDA's approval in 2008, Novartis's octreotide still brought in sales revenue of USD 1589 million in 2013.

After Octreotide made by Novartis entered China in 2004, many local generic drugs came into the market successively. Octreotide has undergone a fast development in China with annual sales value rising from CNY 100 million in 2005 to CNY 466 million in 2014 and CAGR reaching up to 15.8% during the period of 2005-2014. Octreotide enjoys a vast demand in China. Novartis AG (Sweden), Chengdu Tiantaishan Pharmaceutical Co., Ltd, Sinopharm A-THINK Pharmaceutical Co., Ltd, Peking Sunho Pharmaceutical Co., Ltd and Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd all take up certain shares in the Chinese market, among which Novartis AG (Sweden) has the largest market share of over 70%, sales value in 2014 reaching up to CNY 334 million in 2014.

The market size of octreotide in China is expected to keep growing in the next few years.

Readers can get at least the following information from this report:

  • market size of octreotide in China
  • market share of manufacturers of octreotide in China
  • price of octreotide in Chinese market
  • major manufacturers of octreotide in Chinese market
  • market outlook of octreotide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of drugs for endocrine and metabolic regulation
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Octreotide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Octreotide in China

  • 2.1. Patent and Approval Status of Octreotide in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Octreotide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Octreotide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Octreotide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Octreotide in Chinese Hospitals in 2014

  • 6.1. Sandoz GmbH (AT) (Trade Name: Sandostatin LAR)
  • 6.2. Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd
  • 6.3. Wellso Pharmaceutical Co., Ltd
  • 6.4. Peking Sunho Pharmaceutical Co., Ltd
  • 6.5. Sinopharm A-THINK Pharmaceutical Co., Ltd
  • 6.6. GeneScience Pharmaceuticals Co., Ltd
  • 6.7. Chengdu Tiantaishan Pharmaceutical Co., Ltd
  • 6.8. Novartis AG (Sweden) (Trade Name: Sandostatin LAR)

7. Major Manufacturers of Octreotide in Chinese Market, 2010-2014

  • 7.1. Novartis AG (Switzerland)
  • 7.2. Chengdu Tiantaishan Pharmaceutical Co., Ltd
  • 7.3. Sinopharm A-THINK Pharmaceutical Co., Ltd
  • 7.4. Peking Sunho Pharmaceutical Co., Ltd
  • 7.5. Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd

8. Market Outlook of Ooctreotide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent and Approval Status of Octreotide in China
  • Chart Sales Status of Octreotide in China, 2010-2014
  • Chart Sales Value of Octreotide in China, 2010-2014
  • Chart Sales Value of Octreotide in Some Regions in China, 2010-2014
  • Chart Sales Volume of Octreotide in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Octreotide for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Made by Novartis (Switzerland) in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Made by Sinopharm A-THINK in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Made by Shanghai No.1 Biochemical & Pharmaceutical in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Made by Chengdu Tiantaishan in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Injection in China, 2010-2014
  • Chart Price of Octreotide Made by Sandoz GmbH (AT) in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Wellso Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Peking Sunho Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Sinopharm A-THINK Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by GeneScience Pharmaceuticals Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Chengdu Tiantaishan Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Novartis AG (Sweden) in Some Chinese Cities in 2014
Back to Top